84-1174-40　SUMO1 (Small Ubiquitin-related Modifier 1, SUMO-1, Ubiquitin-like Protein SMT3C, SMT3 Homolog 3, Ubiquitin-homology Domain Protein PIC1, Ubiquitin-like Protein UBL1, GAP Modifying Protein 1, GMP1, Sentrin, SMT3C, SMT3H3, UBL1, OK/SW-cl.43) 100ug　S0750-01N

特徴

• Small Ubiquitin-like Modifiers (SUMOs) are a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation.
• Unlike ubiquitination, which targets proteins for degradation, sumoylation participates in a number of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability.
• All SUMO proteins share the conserved ubiquitin domain and the C-terminal diglycine cleavage/attachment site.
• Human SUMO1, also known as Sentrin, UBL1, and SMT3C, is synthesized as a 101aa, 11.5kD propeptide that contains a four aa C-terminal prosegment.
• Following prosegment cleavage, the C-terminal glycine is enzymatically attached to a lysine on a target protein.
• Human SUMO1 shares 100% sequence identity to SUMO1 from mouse.
• SUMO1 is the most unique of the four identified SUMO proteins and shares only 44%, 47%, and 41% sequence identity to SUMO2, SUMO3, and SUMO4, respectively.
• Applications:Suitable for use in Western Blot.
• Other applications not tested.
• Recommended Dilutions:Western Blot: 1ug/ml Optimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized powder may be stored at -20°C.
• Stable for 12 months at -20°C.
• Reconstitute with sterile PBS, 0.02% sodium azide.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• Reconstituted product is stable for 12 months at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.